Editas Medicine, Inc. (EDIT) Key Statistics & Financial Ratios

Editas Medicine, Inc. (EDIT) — Price $2.71 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Editas Medicine, Inc. (EDIT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.

Stock Data

Price$2.71
Market Cap$416M
Enterprise Value$249.6M
Beta2.04
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-3.52
Price / Book2.98
P/S8.59
EV/EBITDA-3.55
EV/Sales5.31
EV/FCF-2.07
P/FCF-3.35
Earnings Yield-22.87%
FCF Yield-28.99%
Dividend Yield0.00%

Profitability

Gross Margin56.90%
EBIT Margin-154.56%
EBITDA Margin-149.40%
Operating Margin-174.71%
Net Margin-157.32%
Return on Equity-196.63%
Return on Assets-31.15%
Return on Invested Capital-46.81%
Return on Capital Employed-48.61%

Financial Health

Current Ratio3.19
Quick Ratio3.19
Cash Ratio2.66
Debt / Equity0.15
Debt / Assets6.53%
Net Debt / EBITDA2.37
Interest Coverage39.05

Per-Share Data

Revenue per share0.39
Book Value per share0.88
Cash per share1.77
FCF per share-1.01
Tangible Book Value per share0.88
Dividend per share0.00

Related companies: ALLO · AVIR · CABA · CAPR · IMMP · KYTX · LYEL

Explore sector: Healthcare · Biotechnology

More sections of EDIT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks